[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-341151-105":59,"doc-detail-341151-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","serum-anti-cfl1-anti-ezr-and-anti-cypa-autoantibody-as-diagnostic-markers-in-ovarian-cancer","Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer","","Study aimed to identify novel autoantibodies against tumor-associated antigens (TAAs) and develop a diagnostic panel for ovarian cancer (OC). Serum enzyme-linked immunosorbent assays quantified five anti-TAA autoantibodies in discovery (70 OC, 70 controls) and validation cohorts (128 OC, 128 controls), with an additional 81 benign ovarian disease samples for specificity. Anti-CFL1, anti-EZR, anti-CYPA (and anti-PFN1) were higher in OC than controls. A combined panel of three markers showed an AUC of 0.762, 55.56% sensitivity, and 81.31% specificity, with utility in CA125/HE4-negative OC subsets.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/serum-anti-cfl1-anti-ezr-and-anti-cypa-autoantibody-as-diagnostic-markers-in-ovarian-cancer/341151/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/serum-anti-cfl1-anti-ezr-and-anti-cypa-autoantibody-as-diagnostic-markers-in-ovarian-cancer/341151.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main purpose of the study?","Question",{"text":112,"@type":113},"To identify novel anti-tumor autoantibodies against tumor-associated antigens and explore a diagnostic panel for ovarian cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the serum autoantibodies measured?",{"text":117,"@type":113},"An enzyme-linked immunosorbent assay (ELISA) detected the expression of five anti-TAA autoantibodies across discovery, validation, and benign disease cohorts.",{"name":119,"@type":110,"acceptedAnswer":120},"Which autoantibodies showed higher expression in ovarian cancer patients?",{"text":121,"@type":113},"Anti-CFL1, anti-EZR, and anti-CYPA were higher in ovarian cancer than in normal controls in both discovery and validation cohorts (anti-PFN1 was also higher).",{"name":123,"@type":110,"acceptedAnswer":124},"How effective was the diagnostic panel combining the three autoantibodies?",{"text":125,"@type":113},"The panel containing anti-CFL1, anti-EZR, and anti-CYPA yielded an AUC of 0.762, with sensitivity of 55.56% and specificity of 81.31%, and it detected about half of CA125-negative, HE4-negative, and ROMA-negative OC cases.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},341151,1790174043,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSerum anti‑CFL1, anti‑EZR, and anti‑CYPA autoantibody as diagnostic markers in ovarian cancer  \nYifan Cheng1,2, Qing Li3,4, Guiying Sun1,2, Tiandong Li1,2, Yuanlin Zou1,2, Hua Ye1,2, Keyan Wang2,3, Jianxiang Shi2,3 & Peng Wang1,2*  \nThe purpose of this study was to identify novel autoantibodies against tumor‑associated antigens (TAAs) and explore a diagnostic panel for Ovarian cancer (OC). Enzyme‑linked immunosorbent assay was used to detect the expression of five anti‑TAA autoantibodies in the discovery (70 OC and 70 normal controls) and validation cohorts (128 OC and 128 normal controls). Machine learning methods were used to construct a diagnostic panel. Serum samples from 81 patients with benign ovarian disease were used to identify the specificity of anti‑TAA autoantibodies for OC. In both the discovery and validation cohorts, the expression of anti‑CFL1, anti‑EZR, anti‑CYPA, and anti‑PFN1 was higher in patients with OC than that in normal controls. The area under the receiver operating characteristic curve, sensitivity, and specificity of the panel containing anti‑CFL1, anti‑EZR, and anti‑CYPA were 0.762, 55.56%, and 81.31%. The panel identified 53.06%, 53.33%, and 51.11% of CA125 negative, HE4 negative and the Risk of Ovarian Malignancy Algorithm negative OC patients, respectively. The  \ncombination of the three anti‑TAA autoantibodies can serve as a favorable diagnostic tool for OC and has the potential to be a complementary biomarker for CA125 and HE4 in the diagnosis of ovarian cancer.  \nKeywords Diagnostic marker, Ovarian cancer, Tumor-associated antigens, Tumor-associated autoantibodies  \nOvarian cancer (OC) is one of the three most common malignancies of the female reproductive system and ranks eighth in morbidity and mortality among all cancers in women1. OC’s lack of specific symptoms, an effective screening, and diagnostic techniques make it difficult to diagnose at an early stage, resulting in poor survival due to metastasis2. However, when the tumor is diagnosed at the early stage, the survival rate can increase to about 90%3. Currently, the most commonly used serological biomarkers for OC screening and diagnosis are tumor-associated antigens (CA125) and human epididymis protein 4 (HE4), but due to their insensitivity to early OC detection and high false positive rates, their predictive utility for OC screening and diagnosis remains suboptimal4–6. Therefore, there is still a need to develop new biomarkers to improve early diagnosis and therapeutic efficacy of OC.  \nDuring the occurrence and progression of tumors, tumor-associated antigens (TAAs) may be produced due to abnormal expression, mutation or post-translational modification of proteins or other reasons. And these TAAs will trigger the immune response to generate anti-TAA autoantibodies7. As a potential source of diagnostic biomarkers, anti-TAA autoantibodies show more advantages than corresponding TAAs: (a) circulating antiTAA autoantibodies exhibit greater stability than corresponding TAAs over time8; (b) the immune response to TAAs results in an amplified signal, such that anti-TAA autoantibodies may be detectable easier and earlier than the TAAs themselves9, 10. As demonstrated by many studies, anti-TAA autoantibodies have been found to be a promising cancer detection tool11, 12, and they have also shown diagnostic potential in the female reproductive system malignancies13, 14.  \n1College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China. 2Henan Key Laboratory of Tumor Epidemiology and State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou 450052, Henan Province, China. 3Henan Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450052, Henan Province, China. 4School of Basic Medical Sciences, Academy of Medical Science, Zhengzhou University, Zhengzhou 450052, Henan, ","cbCaipTz6kaNppGE","https://ap.wps.com/l/cbCaipTz6kaNppGE","pdf",1849014,11,"English","# Purpose\n# Methods\n## Study samples\n# Results\n# Discussion","[{\"question\":\"What was the main purpose of the study?\",\"answer\":\"To identify novel anti-tumor autoantibodies against tumor-associated antigens and explore a diagnostic panel for ovarian cancer.\"},{\"question\":\"How were the serum autoantibodies measured?\",\"answer\":\"An enzyme-linked immunosorbent assay (ELISA) detected the expression of five anti-TAA autoantibodies across discovery, validation, and benign disease cohorts.\"},{\"question\":\"Which autoantibodies showed higher expression in ovarian cancer patients?\",\"answer\":\"Anti-CFL1, anti-EZR, and anti-CYPA were higher in ovarian cancer than in normal controls in both discovery and validation cohorts (anti-PFN1 was also higher).\"},{\"question\":\"How effective was the diagnostic panel combining the three autoantibodies?\",\"answer\":\"The panel containing anti-CFL1, anti-EZR, and anti-CYPA yielded an AUC of 0.762, with sensitivity of 55.56% and specificity of 81.31%, and it detected about half of CA125-negative, HE4-negative, and ROMA-negative OC cases.\"}]","Serum anti-CFL1, anti-EZR, and anti-CYPA autoantibody as diagnostic markers in ovarian cancer | PDF",1790040575,28,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/766ef255a3618f628a6bb5734245661a.webp",983,1291,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ea13df7f2d3b11c196b54c28af3a578.webp",982,1290,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36aeb97e373b471f7c013ff71a5f5d06.webp",981,1289,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4d1e21cb2c0939e48cf364bd09e42a87.webp",980,1287]